ALISO
VIEJO, Calif., Oct. 23,
2023 /PRNewswire/ -- Neuros Medical, Inc., a medical
device company behind an innovative, on-demand bioelectric nerve
block therapy for patients with intractable post-amputation pain,
today announced that David Veino has
been appointed President and Chief Executive Officer. In this
planned transition, Veino will join the Board of Directors. He
succeeds Thomas Wilder, who is
joining the Board as an Independent Director.
David Veino
has been appointed President and Chief Executive Officer of Neuros
Medical
Veino has served as the company's Chief Operating Officer since
2018, during which time he successfully guided the company through
completion of the pivotal clinical trial that evaluated Neuros'
Altius High Frequency Nerve Block System. Upon anticipated PMA
approval from the FDA, Veino will lead the transition of Neuros
from an early-stage company to its commercial execution stage, and
beyond. Mr. Veino is a seasoned commercial leader with 25
years of senior management experience. Prior to Neuros, he
held various roles of increasing responsibility at Stryker, Globus
Medical and Cardiovascular Systems, Inc., (acquired by Abbott).
"The Neuros team has made tremendous progress over the last few
years, culminating in a successful completion of our pivotal
clinical trial and recent submission of the PMA to the FDA," says
David Veino, president and CEO. "We
are one significant step closer to providing a solution of
relieving pain and restoring life for a large, underserved
population of amputees who suffer from debilitating post-amputation
pain."
"On behalf of the entire Neuros Board, I would like to thank Tom
for his leadership and commitment to the company over the past 6
years as President and CEO," said Casey
Tansey, Neuros Director and General Partner at U.S. Venture
Partners (USVP). "Tom guided the company through its formative
years and has built a strong strategy and foundation for the
company's future. We are pleased that he will continue to serve as
an Independent Director and look forward to his continued
leadership on the Board."
In addition, the company announces the appointment of
Randy Ban as an Independent Director
to its Board. Ban currently serves as Chief Commercial Officer of
Inspire Medical Systems (NYSE: INSP), a medical technology
company focused on the development and commercialization of
innovative, minimally invasive solutions for patients with
obstructive sleep apnea.
"I am honored to join the Neuros Board of Directors. The Neuros
Altius system has great potential to help improve the quality of
life for people struggling with post-amputation phantom and
residual limb pain," said Randy
Ban.
In his role at Inspire, Ban was instrumental in progressing the
organization from a clinical to commercial stage enterprise,
successfully building and scaling a high performing field and
account support organization focused on patient centric
outcomes.
"The Neuros team is thrilled to have Randy join our Board," says
Veino. "His experience and insights will be invaluable after the
anticipated PMA approval, as we prepare to transition to a
commercial stage company with a continued focus on delivering
strong and consistent patient outcomes."
Ban joins a highly engaged, talented Board of Directors with a
mission of delivering Neuros' innovative technology to physicians
and their patients who are seeking relief from chronic
post-amputation pain.
About Neuros Medical, Inc.
Neuros Medical, a private neuromodulation company, developed the
Altius system for the treatment of chronic post-amputation pain,
including phantom and residual limb pain. The Altius system
uses Neuros' patented On-Demand Bioelectric Nerve Block Technology
to inhibit pain signal transmission from the damaged nerves near
the site of amputation. The system consists of a nerve cuff
electrode placed around an affected nerve and an implantable pulse
generator (IPG). Patients initiate a 30-minute Altius treatment
session as needed for targeted pain relief.
There are nearly two million amputees in the U.S., with 185,000
new amputations occurring every year. Post-amputation pain includes
both phantom limb pain and residual limb pain, and impacts nearly
one million Americans, representing a significant unmet medical
need, as existing treatment options are limited and consist
primarily of opioids and gabapentinoids.
Caution – Investigational Device. Limited by Federal (or
United States) law to
investigational use.
For additional information regarding Neuros Medical, please
contact:
Paul Unglaub, Sr. Director
Marketing & Communications
punglaub@neurosmedical.com
www.neurosmedical.com
(440) 951-2565
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuros-medical-inc-names-david-veino-as-president-and-ceo-and-expands-board-of-directors-301962333.html
SOURCE Neuros Medical